Evidence for U.S. Preventive Services Task Force (USPSTF) Recommendations Against Routine Mammography for Females between 40-49 Years of Age

  • Published : 2013.03.30


Breast cancer is the most common cancer among females, worldwide, accounting for 22.9% of all cancers (excluding non-melanoma skin cancer) in females. Mammography is a sensitive (77-95%) and specific (94-97%) screening method for breast cancer. Previously, females between the 40-50 years old were recommended to have mammograms every one to two years. However, based on current evidence, in 2009, USPSTF recommended that the decision to start regular, biennial screening mammography for females younger than 50 years should be an individual decision and take patient context into account, including the patient's values regarding specific benefits and harms. This decision was based on findings regarding radiation exposure, false-positive and false-negative rates, over-diagnosis, and pain and psychological responses. The goal of this paper is to focus on evidence for updating the U.S. Preventive Services Task Force (USPSTF) recommendation against routine mammography for females between 40-49 years of age.


  1. Amir E, Freedman OC, Seruga B, Evans DG (2010). Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst, 102, 680-91.
  2. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE (2007). Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med, 146, 516.
  3. Autier P, Boniol M, Gavin A, Vatten LJ (2011). Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Bri Med J, 10, 343.
  4. Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005). The psychological impact of mammographic screening. A systematic review. Psychooncology, 14, 917-38.
  5. Brewer NT, Salz T, Lillie SE (2007). Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med, 146, 502-10.
  6. DeAngelis CD, Fontanarosa PB (2010). US Preventive Services Task Force and breast cancer screening. J Am Med Assoc, 303, 172-3.
  7. DeSantis C, Siegel R, Bandi P, Jemal A (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
  8. Drossaert CH, Boer H, Seydel ER (2001). Does mammographic screening and a negative result affect attitudes towards future breast screening? J Med Screen, 8, 204-12.
  9. Elmore JG, Armstrong K (2005). Screening for breast cancer. J Am Med Assoc, 293, 1245-56.
  10. Food N, Physical Activity and the Prevention of Cancer: a Global Perspective; American Institute for Cancer Research/ World Cancer Research Fund,
  11. Garfinkel L, Boring CC, Heath CW Jr (2009). Changing trends: an overview of breast cancer incidence and mortality. Cancer, 74, 222-7.
  12. Hendrick RE, Helvie MA (2011). United States preventive services task force screening mammography recommendations: science ignored. Am J Roentgenol, 196, 112-6.
  13. Hirsch BR, Lyman GH (2011). Breast cancer screening with mammography. Curr Oncol Rep, 13, 63-70.
  14. Hofvind S, Thoresen S, Tretli S (2004). The cumulative risk of a false-positive recall in the Norwegian breast cancer screening program. Cancer, 101, 1501-7.
  15. Kolb TM, Lichy J, Newhouse JH (2002). Comparison of the performance of screening mammography, physical examination, and breast us and evaluation of factors that influence them: an analysis of 27,825 patient evaluations1. Radiology, 225, 165-75.
  16. Lee CH, Dershaw DD, Kopans D, et al (2010). Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol, 7, 18.
  17. Michell M (2012). Breast screening review-a radiologist's perspective. Bri J Radiology, 85, 845-7.
  18. Moss S (2005). Overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res, 7, 230.
  19. Nelson HD, Huffman LH, Fu R, Harris EL (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann Intern Medicine, 143, 362.
  20. Nelson HD, Tyne K, Naik A, et al (2009). Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med, 151, 727-37.
  21. Nelson HD, Tyne K, Naik A, et al (2009). Screening for breast cancer: systematic evidence review update for the US Preventive Services Task Force. Ann Intern Med, 151, 727.
  22. Qaseem A, Snow V, Sherif K, et al (2007). Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 146, 511-5.
  23. Ravdin PM, Cronin KA, Howlader N, et al (2007). The decrease in breast-cancer incidence in 2003 in the United States. N Eng J Med, 356, 1670-4.
  24. Skaane P (2011). Screening of Breast Cancer. Breast Cancer, a Heterogeneous Disease Entity: 23-44.
  25. Smith RA, Duffy SW (2012). Breast cancer screening: the evolving evidence. Oncology, 26, 471-5.
  26. Spelic D (2010). Dose and image quality in mammography: trends during the first decade of MQSA. US Food and Drug Administration, 2003.
  27. Woolf SH (2010). The 2009 breast cancer screening recommendations of the US preventive services task force. J Am Med Assoc, 303, 162-3.

Cited by

  1. Implementation of Proteomics for Cancer Research: Past, Present, and Future vol.15, pp.6, 2014,
  2. Polycyclic aromatic hydrocarbons and childhood asthma vol.30, pp.2, 2015,